Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters were presented at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place April 13-18, 2024, in Denver, Colorado, USA. Featured presentations described the Company's work in Parkinson's disease and Multiple System Atrophy (MSA), including initial biomarker data and baseline characteristics from the ATH434-201 Phase 2 clinical trial.
致力於開發神經退行性疾病改良療法的生物技術公司Alterity Therapeutics（（澳大利亞證券交易所股票代碼：ATH，納斯達克股票代碼：ATH）（“Alterity” 或 “公司”）今天宣佈，在2024年4月13日至18日在美國科羅拉多州丹佛舉行的美國神經病學學會（AAN）2024年年會上發佈了三張海報。精選演講描述了公司在帕金森氏病和多系統萎縮 (MSA) 方面的工作，包括 ATH434-201 2 期臨床試驗的初始生物標誌物數據和基線特徵。
譯文內容由第三人軟體翻譯。